- Home
- HYFT vs HOWL Comparison
HYFT vs HOWL Comparison
Compare HYFT & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYFT | HOWL |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.5M | 46.7M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HYFT | HOWL |
|---|---|---|
| Price | $1.14 | $0.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.33 | N/A |
| AVG Volume (30 Days) | 289.9K | ★ 395.6K |
| Earning Date | 12-14-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.86 | N/A |
| Revenue Next Year | $22.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $0.27 |
| 52 Week High | $3.00 | $1.33 |
Technical Indicators
Market Signals| Indicator | HYFT | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 37.93 | 49.74 |
| Support Level | $1.03 | $0.88 |
| Resistance Level | $1.50 | $0.99 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 12.50 | 18.53 |
Price Performance
Historical ComparisonAbout HYFT MindWalk Holdings Corp.
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.